Mulenga V - Search Results

1

First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial.

Waalewijn H, Szubert AJ, Wasmann RE, Wiesner L, Chabala C, Bwakura-Dangarembizi M, Makumbi S, Nangiya J, Mumbiro V, Mulenga V, Musiime V, Monkiewicz LN, Griffiths AL, Bamford A, Doerholt K, Denti P, Burger DM, Gibb DM, McIlleron HM, Colbers A; Children with HIV in Africa – Pharmacokinetics and Acceptability of Simple second-line antiretroviral regimens (CHAPAS-4) Trial Team. Waalewijn H, et al. Among authors: mulenga v. Clin Infect Dis. 2023 Sep 18;77(6):875-882. doi: 10.1093/cid/ciad267. Clin Infect Dis. 2023. PMID: 37315296 Free PMC article. Clinical Trial.

2

Diarrhea is a major killer of children with severe acute malnutrition admitted to inpatient set-up in Lusaka, Zambia.

Irena AH, Mwambazi M, Mulenga V. Irena AH, et al. Among authors: mulenga v. Nutr J. 2011 Oct 11;10:110. doi: 10.1186/1475-2891-10-110. Nutr J. 2011. PMID: 21989455 Free PMC article.

3

Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial.

Chintu C, Bhat GJ, Walker AS, Mulenga V, Sinyinza F, Lishimpi K, Farrelly L, Kaganson N, Zumla A, Gillespie SH, Nunn AJ, Gibb DM; CHAP trial team. Chintu C, et al. Among authors: mulenga v. Lancet. 2004 Nov 20-26;364(9448):1865-71. doi: 10.1016/S0140-6736(04)17442-4. Lancet. 2004. PMID: 15555666 Clinical Trial.

4

Determinants of survival without antiretroviral therapy after infancy in HIV-1-infected Zambian children in the CHAP Trial.

Walker AS, Mulenga V, Sinyinza F, Lishimpi K, Nunn A, Chintu C, Gibb DM; CHAP Trial Team. Walker AS, et al. Among authors: mulenga v. J Acquir Immune Defic Syndr. 2006 Aug 15;42(5):637-45. doi: 10.1097/01.qai.0000226334.34717.dc. J Acquir Immune Defic Syndr. 2006. PMID: 16868501

5

Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children.

Mulenga V, Ford D, Walker AS, Mwenya D, Mwansa J, Sinyinza F, Lishimpi K, Nunn A, Gillespie S, Zumla A, Chintu C, Gibb DM; CHAP Trial Team. Mulenga V, et al. AIDS. 2007 Jan 2;21(1):77-84. doi: 10.1097/QAD.0b013e3280114ed7. AIDS. 2007. PMID: 17148971 Clinical Trial.

6

The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children.

Walker AS, Mulenga V, Ford D, Kabamba D, Sinyinza F, Kankasa C, Chintu C, Gibb DM; CHAP Team. Walker AS, et al. Among authors: mulenga v. Clin Infect Dis. 2007 May 15;44(10):1361-7. doi: 10.1086/515396. Epub 2007 Apr 12. Clin Infect Dis. 2007. PMID: 17443476 Clinical Trial.

7

Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia.

Ellis JC, L'homme RF, Ewings FM, Mulenga V, Bell F, Chileshe R, Molyneux E, Abernethy J, van Oosterhout JJ, Chintu C, Walker AS, Gibb DM, Burger DM. Ellis JC, et al. Among authors: mulenga v. Antivir Ther. 2007;12(2):253-60. Antivir Ther. 2007. PMID: 17503667

8

Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets.

L'homme RF, Kabamba D, Ewings FM, Mulenga V, Kankasa C, Thomason MJ, Walker AS, Chintu C, Burger DM, Gibb DM. L'homme RF, et al. Among authors: mulenga v. AIDS. 2008 Mar 12;22(5):557-65. doi: 10.1097/QAD.0b013e3282f4a208. AIDS. 2008. PMID: 18316996 Clinical Trial.

9

Adherence to both cotrimoxazole and placebo is associated with improved survival among HIV-infected Zambian children.

Walker AS, Ford D, Mulenga V, Thomason MJ, Nunn A, Chintu C, Gibb DM, Bangsberg DR. Walker AS, et al. Among authors: mulenga v. AIDS Behav. 2009 Feb;13(1):33-41. doi: 10.1007/s10461-008-9382-4. Epub 2008 Apr 10. AIDS Behav. 2009. PMID: 18401699 Clinical Trial.

10

Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets.

Burger D, Ewings F, Kabamba D, L'homme R, Mulenga V, Kankasa C, Thomason M, Gibb DM, Chintu C, Walker AS. Burger D, et al. Among authors: mulenga v. Ther Drug Monit. 2010 Jun;32(3):369-72. doi: 10.1097/FTD.0b013e3181d75e47. Ther Drug Monit. 2010. PMID: 20386361

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45 results

Search Page

Filters